• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Gerresheimer to manufacture ICOone DPI for Phase 3 trials of ISR’s intranasal COVID-19 vaccine

Gerresheimer has announced that it will manufacture supplies of Iconovo’s IcoOne dry powder inhaler for Phase 3 trials of ISR’s intranasal COVID-19 vaccine and has started the design process for molding and manufacturing the device. In March 2021, Iconovo announced that it would develop an inhaled vaccine for ISR, and in July 2021, Icovono said that it was developing an intranasal version of the ICOone device for the ISR vaccine. According to the announcement, ISR is currently preparing to initiate a Phase 1/2 study of the vaccine in Dhaka, Bangladesh.

ISR CEO Ola Winqvist commented, “We have signed a very important agreement to be able to produce large enough quantities of our game changing inhaler, to cover the needs of our late-stage development studies and our pivotal Phase 3 program.  This agreement also opens the door for further collaborations with Gerresheimer, to produce sufficient quantities of our inhaler to secure our commercial supply chain and the global launch of our exciting dry powder SARS-CoV-2 vaccine.” 

Gerresheimer Medical Systems Executive VP Sales & Marketing, Administration & TCC, Manfred Baumann said, “We are happy and delighted to support ISR with our high expertise in the development, industrialization and manufacturing of drug delivery devices. With our annual production of more than 100 million inhalers we are the ideal partner for ISR.”

Read the Gerresheimer press release.

Share

published on May 31, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews